Overestimate of Fibrosis by FIBROSpect® II in African Americans Complicates the Management of Their Chronic Hepatitis C

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2016 Apr 6

PMID 27047767

Authors

Maher Tama

Paul Naylor

Suhag Patel

Johnny Altawil

Dhiraj Gulati

Fadi Antaki

Milton G Mutchnick

Murray Ehrinpreis

Affiliations

Soon will be listed here.

Abstract

Background: Evaluation of advanced fibrosis in patients with hepatitis C virus (HCV) infection is used to facilitate decisions on treatment strategy and to initiate additional screening measures. Unfortunately, most studies have predominately Caucasian (Cau) patients and may not be as relevant for African Americans (AA).

Aims: This study specifically addresses the issue of defining minimal vs. significant fibrosis in African Americans (AA) with chronic hepatitis C (CHC) using noninvasive assays.

Methods: All patients (n = 319) seen between 1 January 2008 and 30 June 2013 for whom a FibroSpect II® (FSII) assay was performed and had data for calculation of aspartate aminotransferase (AST) platelet ratio index (APRI) and Fibrosis-4 (FIB-4) were identified using the medical records.

Results: When liver biopsy score and FSII assay results for the AA patients with CHC were compared, 31% of AA had advanced FSII fibrosis scores (F2-F4) despite a biopsy score of F0-F1. In contrast, 10% of Cau over-scored. The AA false positive rate was 14% for APRI and 34% for FIB-4. Combining FSII with either APRI (7% false positive) or FIB-4 (10% false positive) improved the false positive rate in AA to 7% (FSII + APRI) and 10% (FSII + FIB-4) but reduced the sensitivity for significant fibrosis.

Conclusions: The FSII assay overestimates fibrosis in AA and should be used with caution since these patients may not have significant fibrosis. If the APRI or FIB-4 assay is combined with the FSII assay, minimal fibrosis in AA can be defined without subjecting the patients to a subsequent biopsy.

References

Gara N, Zhao X, Kleiner D, Liang T, Hoofnagle J, Ghany M . Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2012; 11(3):303-8.e1. PMC: 3642246. DOI: 10.1016/j.cgh.2012.10.044. View

Talaat N, Yapali S, Fontana R, Conjeevaram H, Lok A . Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. J Viral Hepat. 2014; 22(5):481-8. DOI: 10.1111/jvh.12343. View

Zarski J, Sturm N, Guechot J, Zafrani E, Vaubourdolle M, Thoret S . Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One. 2013; 8(3):e59088. PMC: 3605459. DOI: 10.1371/journal.pone.0059088. View

Patel K, Benhamou Y, Yoshida E, Kaita K, Zeuzem S, Torbenson M . An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat. 2009; 16(3):178-86. DOI: 10.1111/j.1365-2893.2008.01062.x. View

Shiffman M, Benhamou Y . Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver Int. 2013; 33 Suppl 1:105-10. DOI: 10.1111/liv.12066. View

Mendeni M, Foca E, Gotti D, Ladisa N, Angarano G, Albini L . Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis. 2011; 52(9):1164-73. DOI: 10.1093/cid/cir071. View

Sebastiani G, Gkouvatsos K, Pantopoulos K . Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014; 20(32):11033-53. PMC: 4145747. DOI: 10.3748/wjg.v20.i32.11033. View

Patel K, Nelson D, Rockey D, Afdhal N, Smith K, Oh E . Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008; 6(2):242-7. DOI: 10.1016/j.cgh.2007.11.009. View

Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H . Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53(6):1013-21. DOI: 10.1016/j.jhep.2010.05.035. View

10.

Zaman A, Rosen H, Ingram K, Corless C, Oh E, Smith K . Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med. 2007; 120(3):280.e9-14. DOI: 10.1016/j.amjmed.2006.06.044. View

11.

Carlson J, Kowdley K, Sullivan S, Ramsey S, Veenstra D . An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol. 2009; 24(5):786-91. PMC: 3676667. DOI: 10.1111/j.1440-1746.2009.05778.x. View

12.

Myers R, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M . Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2011; 56(3):564-70. DOI: 10.1016/j.jhep.2011.10.007. View

13.

Morishita N, Hiramatsu N, Oze T, Harada N, Yamada R, Miyazaki M . Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. J Gastroenterol. 2013; 49(7):1175-82. DOI: 10.1007/s00535-013-0877-z. View

14.

Manning D, Afdhal N . Diagnosis and quantitation of fibrosis. Gastroenterology. 2008; 134(6):1670-81. DOI: 10.1053/j.gastro.2008.03.001. View

15.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

16.

Smith J, Sterling R . Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009; 30(6):557-76. DOI: 10.1111/j.1365-2036.2009.04062.x. View

17.

Baran B, Gulluoglu M, Soyer O, Ormeci A, Gokturk S, Evirgen S . Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat. 2014; 21(2):111-20. DOI: 10.1111/jvh.12127. View

18.

Castera L . Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012; 142(6):1293-1302.e4. DOI: 10.1053/j.gastro.2012.02.017. View

19.

Stibbe K, Verveer C, Francke J, Hansen B, Zondervan P, Kuipers E . Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011; 46(7-8):962-72. DOI: 10.3109/00365521.2011.574725. View

20.

Macias J, Gonzalez J, Ortega E, Tural C, Cabrero E, Burgos A . Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Med. 2010; 11(7):439-47. DOI: 10.1111/j.1468-1293.2009.00812.x. View